PT - JOURNAL ARTICLE AU - Brennan Klein AU - Ana C. Zenteno AU - Daisha Joseph AU - Mohammadmehdi Zahedi AU - Michael Hu AU - Martin Copenhaver AU - Moritz U.G. Kraemer AU - Matteo Chinazzi AU - Michael Klompas AU - Alessandro Vespignani AU - Samuel V. Scarpino AU - Hojjat Salmasian TI - Forecasting hospital-level COVID-19 admissions using real-time mobility data AID - 10.1101/2022.06.06.22275840 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.06.22275840 4099 - http://medrxiv.org/content/early/2022/06/08/2022.06.06.22275840.short 4100 - http://medrxiv.org/content/early/2022/06/08/2022.06.06.22275840.full AB - For each of the COVID-19 pandemic waves, hospitals have had to plan for deploying surge capacity and resources to manage large but transient increases in COVID-19 admissions. While a lot of effort has gone into predicting regional trends in COVID-19 cases and hospitalizations, there are far fewer successful tools for creating accurate hospital-level forecasts. At the same time, anonymized phone-collected mobility data proved to correlate well with the number of cases for the first two waves of the pandemic (spring 2020, and fall-winter 2021). In this work, we show how mobility data could bolster hospital-specific COVID-19 admission forecasts for five hospitals in Massachusetts during the initial COVID-19 surge. The high predictive capability of the model was achieved by combining anonymized, aggregated mobile device data about users’ contact patterns, commuting volume, and mobility range with COVID hospitalizations and test-positivity data. We conclude that mobility-informed forecasting models can increase the lead-time of accurate predictions for individual hospitals, giving managers valuable time to strategize how best to allocate resources to manage forthcoming surges.Competing Interest StatementS.V.S. holds unexercised options in Iliad Biotechnologies. This entity provided no financial support associated with this research, did not have a role in the study design, and did not have any role during its execution, analyses, interpretation of the data or decision to submit.Funding StatementA.V. and M.C. acknowledge support from COVID Supplement CDC-HHS-6U01IP001137-01 and Cooperative Agreement no. NU38OT000297 from the Council of State and Territorial Epidemiologists (CSTE). M.C. and A.V. acknowledge support from the Google Cloud Research Credits program. A.V. acknowledges support from the McGovern Foundation and the Chleck Family Foundation. The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the funding agencies, The Rockefeller Foundation, the National Institutes of Health, or U.S. Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In addition to time series data of statewide test positivity percentages from the Massachusetts Department of Public Health, two other data sources were used in this research: aggregated location data from mobile devices and hospital admission data. Because both data sources were only used in aggregated form, the Institutional Review Board (IRB) at Northeastern University determined that the study does not qualify as human subject research and is exempt from IRB approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.